ofa semaglutide lawsuit Files Another Against the FDA, This Time Over 🚨 The drama around Ozempic

One study demonstrated a 26% reduction in the risk of major adverse cardiovascular events (MACE) for patients using semaglutide

Ozempic is FDA approved for blood sugar control in people with Type 2 diabetes, as well as cardiovascular risk reduction in people with Type 2 diabetes and heart disease

2021 Wegovy (semaglutide) A pivotal moment in obesity treatment, demonstrating unprecedented weight-loss outcomes and changing both clinical practice and public perception

Holding at a dose for an extra 4 weeks before escalating is a medically supported strategy when: Nausea or vomiting persists beyond 2 weeks at the current dose You are unable to eat at least 1,000 calories per day comfortably Dehydration symptoms appear (dark urine, dizziness on standing, dry mouth) You are losing weight faster than 1 to 2 pounds per week on the current dose (aggressive weight loss increases side effect risk) In the STEP trials, delayed escalation did not compromise overall weight loss outcomes at 68 weeks

Whole milk

Injection site reactions occurred in 1.9-4.5% of tirzepatide recipients compared to just 0.2% of semaglutide recipients in the SURPASS-2 trial